Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABS-001
- Development stage
- Preclinical
- Lead developer
- Agastiya Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
ABS-001 is an investigational mesenchymal stem cell (MSC) therapy being developed by Alpha Biomedical for the treatment of age-related frailty. Mesenchymal stem cells are multipotent stromal cells characterized by their ability to differentiate into various cell types and their potent immunomodulatory, anti-inflammatory, and regenerative properties. ABS-001 is designed to address the systemic chronic inflammation (often termed 'inflammaging') and tissue degeneration associated with aging, with the goal of improving physical function and resilience in elderly individuals. The therapy is currently in the preclinical stage of development.
Beyond the preview
Go deeper on ABS-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABS-001.